Table 1.

Demographic information, neoadjuvant therapy and biliary interventions.

Age	67 (61.3–76.0)
Male sex	30 (51%)
BMI	27.2 (24.1–31.1)
Race
Black	6 (10%)
White	51 (86%)
Hispanic	1 (2%)
Asian	1 (2%)
ASA
II # (%)	6 (10%)
III # (%)	52 (88%)
IV # (%)	1 (2%)
Ultimate Stage
IA # (%)	8 (14%)
IB # (%)	12 (20%)
IIA # (%)	10 (17%)
IIB # (%)	20 (34%)
III # (%)	6 (10%)
IV # (%)	3 (5%)
Neoadjuvant Regimen
Gemcitabine/nab-paclitaxel ± chemoradiation	29 (49%)
FOLFIRINOX ± chemoradiation	14 (24%)
Combo FOLFIRINOX ± gemcitabine/nab-paclitaxel	8 (14%)
Other	8 (14%)
# cycles	4.0 (3.0–6.0)
# patients with cycles unknown	7
ERCP with stent
Metal ➜ Metal	1
Plastic ➜ Metal	2
New metal	2
PTHD	4
Percutaneous cholecystostomy	3
Cholecystectomy	2
Medical treatment of cholangitis	2